Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Festival Offer
This Diwali, Light up your portfolio with MoneyWorks4me Superstars starting @ ₹ 7,999 ₹ 5,999 (Offer valid till 3rd Nov 21)
investing succesffuly to reach your goals investing succesffuly to reach your goals

Plethico Pharmaceuticals Ltd Stock Analysis

Small Cap
Evaluated by 263 users | BSE: 532739 | NSE: PLETHICO |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
Return on Capital Employed 28.9%20.23%19.66%20.09%9.25%9.4%6.67%0.64%-0.37%1.55%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 160222319440471471443406475425130
Y-o-Y Gr. Rt.-38.6%43.7%37.9%7.2%-0%-6%-8.2%17%-10.6%-
Adjusted EPS (Rs.) 14.9218.8123.8334.0126.5828.2817.69-14.08-13.09-7.17-80.32
Y-o-Y Gr. Rt.-26.1%26.7%42.7%-21.9%6.4%-37.5%-179.6%NANA-
Book Value per Share (Rs.) 54.8486.3128.36137.57177.38198.06204.82189.36160.67126.4976.04
Adjusted Net Profit 45.457.281.211690.696.360.3-48-44.6-24.4-274
Net Op. Cash Flow (Rs. Cr.) 8425.5-23.948.458.9150103-119-5133.9-
Debt to Cash Flow from Ops 0.52.66-3.966.3311.073.935.66-7.32-19.8524-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Plethico Pharmaceuticals Ltd. should be analysed on a Standalone basis
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 11.5%-2%-1.4%-10.6%
Adjusted EPS -192.2%-177%-174%NA
Book Value per Share 9.7-6.5-14.8-21.3
Share Price - - - -
Key Financial Parameter
Performance Ratio Colour Code Guide
Return on Equity (%) 36.0724.292327.9315.0614.968.75-7.03-7.36-5.62-79.32
Operating Profit Margin (%) 6.4130.8328.5729.3819.5328.3228.0610.46-0.047.453.98
Net Profit Margin (%) 28.3525.7825.4826.3619.2320.4613.61-11.81-9.38-5.75-211.28
Debt to Equity
Working Capital Days 1811742111923023353424825425175454
Cash Conversion Cycle 153158189158228251272420489467-
Loading price chart...
Entity Percentage Holding
Promoters 57.75%
Institutions 19.41%
Non-Institutions 22.84%
Pledged *86.7386.1485.9385.7585.7485.7485.6585.5759.1882.29
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Data is not available for this company.

Data is not available for this company

Data is not available for this company.

Plethico Pharmaceuticals, established in 1991, is a leading global healthcare / pharmaceutical company with a strong emphasis on herbal and neutraceutical segments. The company focused on manufacturing and marketing a range of branded generic pharmaceutical formulations, has rapidly evolved and now engages in the manufacture, marketing and distribution of pharmaceutical and allied healthcare products in the neutraceutical and herbal segments in India and internationally. Domestically,

Plethico Pharmaceuticals, established in 1991, is a leading global healthcare / pharmaceutical company with a strong emphasis on herbal and neutraceutical segments. The company focused on manufacturing and marketing a range of branded generic pharmaceutical formulations, has rapidly evolved and now engages in the manufacture, marketing and distribution of pharmaceutical and allied healthcare products in the neutraceutical and herbal segments in India and internationally. Domestically, Plethico operates in the segments of sports nutrition, confectionary and OTC, in India.

In addition to India in the OTC segment, Plethico is also a leading player in the Commonwealth of Independent States (CIS), Africa, South East Asia, Latin America and in the GCC for its Travisil range of products. With the recent acquisition of Natrol – a leading manufacturer and marketer of branded nutritional products in the United States, Plethico has now expanded its global footprint to the regulated markets of the United States and Europe.

With over 400 product approvals, operations in more than 25 countries, and exports to over 45 countries, Plethico continues to build on its strength of developing synergistic alliances and strengthen its supply chain management, particularly for the exciting and challenging overseas markets.

Plethico has established itself as a dominant player in regions including the CIS, Africa, Latin America and South East Asia. Fully owned subsidiaries, joint ventures, acquisitions and Plethico’s own distribution networks have enabled the company to emerge as a strong competitor in the global markets.

Product range of the company includes:

  • Herbal Healthcare Products A range of clinically proven herbal products developed from scientifically validated herbal extracts, offers a safe and natural alternative in treating lifestyle related disorders like diabetes, cholesterol, sleep disorders, digestive disorders and pain management.
  • Consumer Healthcare Products & Neutraceuticals With an increasing trend towards direct to consumer marketing, the launch of fast moving consumer healthcare products, offers immense potential both in the Indian as well as the global markets. The consumer products consists of a range of products in the sports nutrition, confectionary, pharma OTC and herbal supplements category. Other products in this segment includes products in the oral hygiene, footcare, digestive care and cough & cold categories.
  • Pharmaceutical Formulations With over 400 different formulations in more than 39 therapeutic segments, Plethico has a strong presence in Anti-malarials, Anti-tubercular, Anti-infectives, Pain, Cardiac, Gastro and Cough & Cold. Identification of new therapeutic categories, products, innovation in drug delivery systems & patient compliance is the basis of our product selection.
  • Hospital Consumables, Disposable & Veterinary Products A range of quality Hospital consumables, Disposables, Sutures & Diagnostic kits, has given it the necessary edge for the large market for hospital products.The introduction of Veterinary products marks our entry into the yet unexplored Veterinary segment.


  • 1963-70 The beginning of the group activity. This decade saw the establishment of the company's first formulation plant, manufacturing tablets, capsules and liquid orals, at Indore, Madhya Pradesh, India.
  • 1971-80 Up-gradation and expansion of manufacturing facilities. Establishment of a nation wide marketing and distribution network. Introduction of branded formulations in various categories.
  • 1981-90 An ultra modern formulation plant was established at Manglia, near Indore, to manufacture a wide range of allopathic formulations. Innovative branded formulations were introduced and established in Anti-malarials, Anti-tubercular, Cardiovascular & Cough & Cold segments. The company pioneered the launch of Doxycycline and Cotrimoxazole in the Indian market.
  • 1991-2000 Diversification into herbal & natural formulations with scientific and modern manufacturing plant for Herbals set up at Indore.Introduction of novel herbal products for Hepatocare, Diabetes and Syndrome X developed with in-house research and clinical evidence.
  • 2000-2005 Commissioning of the state of the art formulation manufacturing plant at Kalaria, Indore, as per the requirements of WHO GMP, UK MHRA and US FDA.The company re-oriented its business strategy and launched its Consumer Healthcare Division in India.Ultra modern fully integrated plants set up for manufacture of PET bottle (AOKI, Japan) and hard boiled candies (Klockner Hansel GmBH, Germany).The company acquired a marketing and distribution chain in the CIS, with subsidiaries in Russia, Ukraine, Kazakhstan, Moldova, Azerbaijan and Kyrgyzstan. Marketing and Distribution Joint Ventures formed in South East Asia, Africa and Latin-America.Establishment of Plethico Africa Limited (Kenya), a manufacturing Joint Venture to cater to the East African market.
  • 2006 - 2008 Plethico raises Rs 110 crore through an IPO to part finance:-The up-gradation of its Kalaria plant to make it UK MHRA compliant. -Setting up a WHO GMP (World Health Organisation Good Manufacturing Practices) compliant plant in Jammu & Kashmir and land to be used for organic farming of important herbs. -Setting up a R&D and formulation and development centre. -Acquiring stake in domestic herbal/OTC/nutraceutical company or a brand. -Setting up its corporate office in Mumbai. -The working capital needs.
  • Activating brokers for International Acquisition: The process was started in November, 2006. The objective was to acquire a synergistic business in the US. Company evaluated proposals ranging from $ 15 Milllion to $ 60 Million. This search helped Plethico to get a first hand feel on what is available in the US markets in this range. A senior management team was deployed in April 07 to start meetings with prospective sellers and to undertake a detailed evaluation process before taking a decision to invest.
  • Acquisition sighted: The company quickly locked in on a probable list of target companies it had identified after visit during the April visit.Funding by Foreign Currency Convertible Bonds (FCCB): Company successfully raised $ 75 Million for financing the prospective deal in hand. The company identified Natrol Inc (NTOL) a Nasdaq listed entity manufacturing and marketing Herbal and nutraceutical formulations in the US. It had a retail reach of more than 55000 outlets. The target was to be acquired through a friendly merger deal which was announced on 18th November, 2007 for cash at $ 80.8 Million. The company's annual revenues were approximately $100 Million with a projected EBlTDA of 10%.
  • Sale of stake in Rezlov: The company in 2003 had started acquiring strategic stake in Rezlov Group of Companies in CIS starting all across at 51 % stake. In the meantime, Company had increased stake to 75% in 3 Companies. Plethico sold stake in 2007 in all the Companies to accommodate a new strategic partner from Switzerland who took stake in all the six entities. The objective of disinvestment was not to earn INR 16.46 Crores of profit for diluting stake or to make the holding uniform in all entities at 45%. The objective was to bring in a strategic partner who would help our cause of deepening our reach in European markets starting from East European markets.

Different divisions of the company :

  • Nutriscience
  • Confectionary
  • Pharma OTC and herbal supplements category.

Achievements/ recognition :

  • Plethico brand topped the Anti-Malarial segment of quinines. (A C Neilson 2002).
  • Plethico, ranked amongst the TOP 5 Anti-TB companies in India, with its revolutionary 3/4 drug fixed dose Anti-TB combinations.
  • Major thrust into International Marketing. Travisil, an indigenously developed herbal Cough & Cold product became a star performer in the entire CIS market.

Future plans :

Plethico is planning to enter the areas of immunomodulation, gynecological disorders and antioxidants in the near future.

The company also plans to manufacture and market Natrol’s top brands in India and also make them available in the stronghold semi-regulated markets. Simultaneously, It plans to launch its leading homegrown brand Travisil and Actifresh SF in the US market.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323